Elevance (ELV) Medicaid margin recovery pushed out to 2027-28 - Mizuho
Tweet Send to a Friend
Mizuho analyst Ann Hynes reiterated an Outperform rating and $505.00 price target on Elevance (NYSE: ELV) following cautious commentary on ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


